已收盘 02-06 16:00:00 美东时间
+0.170
+0.65%
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia Arrowhead Pharmaceuticals Inc. has announced the initiation of a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being developed for the treatme
01-28 01:02